Triochem Products Limited to Consider Q2 FY27 Results November 4

Triochem Products Limited will consider and approve its unaudited Q2 FY27 and half-year financial results on November 4, 2026, after reporting zero revenue from operations and a net profit of ₹0.0948 crore in Q1 FY27. The meeting will provide the next formal update on the company’s operating position.

What will Triochem Products Limited consider on November 4?

Triochem Products Limited has informed the BSE that its Board of Directors will meet at 3:00 p.m. on Wednesday, November 4, 2026, at the company’s registered office. The principal agenda is the consideration and approval of unaudited financial results for the quarter and half year ended September 30, 2026.

The board may also take up other matters with the chair’s permission. The company’s October 24 intimation stated that the trading window had been closed from October 1 in connection with the results process. Such trading-window restrictions are used to limit dealing in securities while unpublished price-sensitive information is being prepared and reviewed.

The November 4 meeting is material because it will disclose Triochem Products’ financial performance for the September quarter, following a June quarter in which the company recorded a profit without any revenue from its stated operations. The results will also cover the first six months of FY27, offering a broader view of income, expenses and profitability than the June-quarter statement alone.

What did Triochem Products report in Q1 FY27?

Triochem Products reported net profit of ₹0.0948 crore for the quarter ended June 30, 2026, compared with a net loss of ₹0.0306 crore in the corresponding quarter of the prior year. Revenue from operations was nil in both periods, while the Q1 FY27 profit was supported by other income and a significant reduction in expenses.

Other income stood at ₹0.1656 crore in Q1 FY27, against ₹0.2210 crore a year earlier. Total expenses declined to ₹0.0417 crore from ₹0.3734 crore. As a result, profit before tax was ₹0.1239 crore, compared with a loss before tax of ₹0.1524 crore in Q1 FY26. Tax expense of ₹0.0291 crore resulted in the reported net profit.

The Q1 results were approved by the board on August 14, 2026, after review by the Audit Committee. Kanu Doshi Associates LLP, the statutory auditor, issued an unqualified conclusion on the unaudited quarterly financial results, according to the information provided by the company.

Why are the Q2 FY27 results important for investors?

The Q2 FY27 results are important because Triochem Products’ recent profits have not been supported by operating revenue. The company operates in the chemical and pharmaceuticals segment, but it reported no manufacturing activity and nil operating revenue during FY26. Its June-quarter income was entirely classified as other income.

The company’s FY26 outcome was also shaped by a non-recurring asset transaction. Shareholders approved the FY26 financial statements at the 54th Annual General Meeting held on August 22, 2026. FY26 net profit was ₹7.9707 crore, compared with a net loss of ₹0.4001 crore in FY25, following an exceptional gain of ₹11.1665 crore from the sale of immovable properties, plant and machinery.

Before exceptional items and tax, Triochem Products recorded an FY26 operational loss of ₹0.6485 crore, wider than ₹0.2462 crore in the previous year. The company had said that liquidity was more comfortable after monetising non-core assets, while citing post-pandemic challenges in relationship-driven sales. The September-quarter results will show whether income, costs or operations changed after the June quarter.

No share-price movement or market-volume data has been provided with the board-meeting notice. For investors, the key disclosed financial markers remain the absence of operating revenue, the level of other income, the cost base and the effect of prior asset monetisation on reported earnings.

How could the board meeting affect Triochem Products’ disclosures?

The board meeting will result in the formal release of unaudited September-quarter and half-year figures, subject to the board’s approval. These disclosures are expected to clarify whether Triochem Products continued to report nil sales, generated other income, or recorded changes in expenses and profitability during the period ended September 30.

The meeting does not itself establish an operational recovery, capital allocation decision or new business plan. The company has only said that the board will consider the financial results and any other business permitted by the chair. Therefore, any assessment of its current operations will depend on the specific figures and notes released after the meeting.

Conclusion

Triochem Products Limited’s November 4 board meeting is focused on the approval of Q2 FY27 and first-half results. The update follows a Q1 FY27 net profit of ₹0.0948 crore, achieved despite nil operating revenue, and an FY26 profit that was substantially influenced by a ₹11.1665 crore exceptional gain on asset sales.

Investors should watch the company’s September-quarter revenue from operations, other income, expense levels and any commentary on manufacturing activity or liquidity. The board’s results announcement on November 4 is the scheduled disclosure that will provide those details.